Literature DB >> 32156706

Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus.

Konstantinos Tselios1, Dafna D Gladman2, Jiandong Su3, Murray Urowitz4.   

Abstract

BACKGROUND: The 2017 American College of Cardiology/American Heart Association guidelines defined hypertension at ≥130/80 mm Hg. Studies on patients with connective tissue diseases were not considered. Our aim was to assess the impact of this definition on atherosclerotic vascular events (AVEs) in systemic lupus erythematosus. PATIENTS
METHODS: Individuals from the Toronto Lupus Clinic with at least 2 years of follow-up and no prior AVE were divided in three groups according to their mean blood pressure (BP) over that period (≥140/90 mm Hg, 130-139/80-89 mm Hg and <130/80 mm Hg). They were followed until the first occurrence of an AVE (fatal or non-fatal coronary artery disease, cerebrovascular event and peripheral vascular disease) or last visit. Groups were compared as per the baseline atherosclerotic risk factors. A multivariable time-dependent analysis was performed to adjust for the presence of other risk factors.
RESULTS: Of 1532 patients satisfying the inclusion criteria, 155 (10.1%) had a BP ≥140/90 mm Hg, 316 (20.6%) 130-139/80-89 mm Hg and 1061 (69.3%) were normotensives. After a mean follow-up of 10.8 years, 124 AVEs were documented. The incidence rates were 18.9, 11.5 and 4.5 per 1000 patient-years for the three groups, respectively (p=0.0007 between the 130-139/80-89 mm Hg group and the normotensives). A mean BP of 130-139/80-89 mm Hg over the first 2 years was independently associated with the occurrence of AVEs (HR 1.73, 95% CI 1.13 to 2.65, p=0.011).
CONCLUSION: Patients with lupus with a sustained mean BP of 130-139/80-89 mm Hg over 2 years had a significantly higher incidence of AVEs compared with normotensive individuals. This BP level should be the target for antihypertensive therapy to minimise their cardiovascular risk. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  atherosclerosis; cardiovascular disease; systemic lupus erythematosus

Mesh:

Substances:

Year:  2020        PMID: 32156706     DOI: 10.1136/annrheumdis-2019-216764

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

Review 1.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 2.  Cardiovascular disease in systemic lupus erythematosus.

Authors:  Maureen McMahon; Richard Seto; Brian J Skaggs
Journal:  Rheumatol Immunol Res       Date:  2021-12-15

Review 3.  Should Renal Inflammation Be Targeted While Treating Hypertension?

Authors:  Sarika Chaudhari; Grace S Pham; Calvin D Brooks; Viet Q Dinh; Cassandra M Young-Stubbs; Caroline G Shimoura; Keisa W Mathis
Journal:  Front Physiol       Date:  2022-06-13       Impact factor: 4.755

4.  Associations between glucocorticoids, antiphospholipid antibodies and femur head necrosis in patients with SLE: a directed acyclic graph-based multicentre study.

Authors:  Shengbao Chen; Qianying Cai; Yanjun Xu; Qiong Fu; Yong Feng; Xiaoxiang Chen; Shengming Dai; Dongbao Zhao; Ce Zhan; Weidong Xu; Jiwei Wang; Yang Wang; Jinming Yu; Chunde Bao; Changqing Zhang
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

Review 5.  Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.

Authors:  Emily Keyes; Madison Grinnell; Douglas Jacoby; Thomas Vazquez; DeAnna Diaz; Victoria P Werth; Kevin Jon Williams
Journal:  Int J Womens Dermatol       Date:  2021-09-09

6.  Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.

Authors:  Manuel Francisco Ugarte-Gil; Anselm Mak; Joanna Leong; Bhushan Dharmadhikari; Nien Yee Kow; Cristina Reátegui-Sokolova; Claudia Elera-Fitzcarrald; Cinthia Aranow; Laurent Arnaud; Anca D Askanase; Sang-Cheol Bae; Sasha Bernatsky; Ian N Bruce; Jill Buyon; Nathalie Costedoat-Chalumeau; Mary Ann Dooley; Paul R Fortin; Ellen M Ginzler; Dafna D Gladman; John Hanly; Murat Inanc; David Isenberg; Soren Jacobsen; Judith A James; Andreas Jönsen; Kenneth Kalunian; Diane L Kamen; Sung Sam Lim; Eric Morand; Marta Mosca; Christine Peschken; Bernardo A Pons-Estel; Anisur Rahman; Rosalind Ramsey-Goldman; John Reynolds; Juanita Romero-Diaz; Guillermo Ruiz-Irastorza; Jorge Sánchez-Guerrero; Elisabet Svenungsson; Murray Urowitz; Evelyne Vinet; Ronald F van Vollenhoven; Alexandre Voskuyl; Daniel J Wallace; Michelle A Petri; Susan Manzi; Ann Elaine Clarke; Mike Cheung; Vernon Farewell; Graciela S Alarcon
Journal:  Lupus Sci Med       Date:  2021-12

Review 7.  Systemic Lupus Erythematosus and Cardiovascular Disease.

Authors:  Surajkumar B Jha; Ana P Rivera; Gabriela Vanessa Flores Monar; Hamza Islam; Sri Madhurima Puttagunta; Rabia Islam; Sumana Kundu; Ibrahim Sange
Journal:  Cureus       Date:  2022-02-08

Review 8.  Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?

Authors:  Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.